source
- ADC Therapeutics' confirmatory data for Zynlonta muddied by death ratesADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...Endpoints · 1mo ago↗ source
- ADC biotech Ona Therapeutics secures $86.6M in Series B raiseBarcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic. CEO Valerie Vanhooren told Endpoints News in an interview that the cash…Endpoints · 1mo ago↗ source
- A Spanish biotech banks $87M to make differentiated ADCsOna Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.